

Visiting The Investigators: Prevention and Management of Tumor Lysis Syndrome, Neutropenia and Other Toxicities Associated with Novel Therapies for Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following regimens was evaluated as a time-limited therapy in comparison to chlorambucil/obinutuzumab in the Phase III CLL14 study for patients with previously untreated chronic lymphocytic leukemia (CLL)?
 - Venetoclax/obinutuzumab
 - Venetoclax/rituximab
 - Venetoclax/ibrutinib
- At the 2021 ASCO Annual Meeting, results of the ELEVATE-RR head-to-head trial evaluating acalabrutinib versus ibrutinib for previously treated high-risk CLL were presented. Which of the following outcomes in terms of any-grade atrial fibrillation was demonstrated?
 - A higher rate with acalabrutinib
 - A higher rate with ibrutinib
 - Similar rates with acalabrutinib and ibrutinib
- Which of the following conditions has been associated with tumor lysis syndrome (TLS) in patients receiving venetoclax for CLL?
 - Hyperkalemia only
 - Hyperuricemia only
 - Hypercalcemia only
 - Hyperkalemia, hyperuricemia and hypercalcemia have all been associated with venetoclax-related TLS
- The Phase III ALPINE study compared which of the following agents to ibrutinib for patients with relapsed/refractory CLL?
 - Acalabrutinib
 - Pirtobrutinib
 - Zanubrutinib
- Which of the following statements is FALSE regarding the neutropenia associated with venetoclax-based therapy?
 - It requires the monitoring of blood counts, with nuanced management as medically appropriate
 - It can be managed by growth factor support such as GCSF
 - It usually occurs late in the course of therapy (after the first 6 months)
- Which of the following statements is FALSE regarding the atrial fibrillation associated with ibrutinib?
 - Most cases are higher than Grade 3 in severity
 - It increases the risk of heart failure
 - The incidence is between 4% and 16%
- Strategies to treat hyperphosphatemia associated with TLS in patients receiving venetoclax-based therapy include which of the following?
 - Intravenous hydration only
 - Phosphate binders only
 - Continuous renal replacement therapy (CRRT) only
 - Hydration, phosphate binders and CRRT are all strategies to treat TLS-associated hyperphosphatemia
- Which of the following side effects has been reported with allopurinol used in the management of TLS?
 - Rash only
 - Hepatic toxicity only
 - Stevens-Johnson syndrome only
 - Rash, hepatic toxicity and Stevens-Johnson syndrome have all been reported

Visiting The Investigators: Prevention and Management of Tumor Lysis Syndrome, Neutropenia and Other Toxicities Associated with Novel Therapies for Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. The ongoing Veneto-STOP trial is investigating a minimum duration of venetoclax therapy of how long for patients with CLL and negative MRD assessments?
- a. Three months
 - b. Six months
 - c. Twelve months
10. Which of the following statements is TRUE regarding the hypertension associated with ibrutinib?
- a. New or worsening hypertension is associated with an increased risk of major cardiovascular events
 - b. Initiation of new antihypertensive therapy resulting in controlled hypertension is not associated with a decreased risk of subsequent major cardiovascular events